Ultimovacs - Edison Group

Overview
Price performance
Financials
Research
Thematics

Edison Investment Research is terminating coverage on Ultimovacs (ULTI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Latest Insights

View More

Healthcare |
Flash note

18.04.24

Ultimovacs — Steadfast commitment to UV1 progression

Healthcare |
Flash note

07.03.24

Ultimovacs — UV1 hits transitory roadblock with INITIUM top-line

Healthcare |
Flash note

04.03.24

Ultimovacs — Peer-reviewed publication reiterates UV1’s potential

Healthcare |
edison tv

27.02.24

Ultimovacs – executive interview

Ultimovacs_resized

Sector

Healthcare

Balance Sheet

Forecast net debt (NOKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	6.9	(93.9)	(93.6)
Relative	5.1	(94.4)	(94.3)
52 week high/low	NOK160.4/NOK6.3

Financials

Edison Investment Research is terminating coverage on Oxford Cannabinoid Technologies (OCTP), Britvic (BVIC), Ultimovacs (ULTI), DFR Gold (DFR), The Merchants Trust (MRCH), PB Holding (PBH) and Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Dec	Revenue (NOKm)	EBITDA (NOKm)	PBT (NOKm)	EPS (fd) (öre)	P/E (x)	P/CF (x)
2022A	0.0	(181.0)	(167.8)	(489.9)	N/A	N/A
2023A	0.0	(213.0)	(189.2)	(550.1)	N/A	N/A
2024E	N/A	N/A	N/A	N/A	N/A	N/A
2025E	N/A	N/A	N/A	N/A	N/A	N/A

Ultimovacs_resized

Flash note

Healthcare

02.11.23

Ultimovacs — Line of sight on INITIUM top-line readout

research

Healthcare

18.10.23

Ultimovacs — Overall survival is the name of the NIPU PII game

Ultimovacs_resized

Flash note

Healthcare

12.10.23

Ultimovacs — Two for two in melanoma Phase I trial

Ultimovacs_resized

Flash note

Healthcare

10.10.23

Ultimovacs — UV1 ODD a sign of positive things to come

Update

Healthcare

24.08.23

Ultimovacs — Gearing up for UV1 Phase II trial readouts

Flash note

Healthcare

04.08.23

Ultimovacs — FOCUS – first in series of upcoming catalysts

Ultimovacs_resized

Flash note

Healthcare

20.06.23

Ultimovacs — Positive Phase I update in malignant melanoma

Update

Healthcare

12.06.23

Ultimovacs — UV1 by no means out after NIPU readout

Update

Healthcare

15.05.23

Ultimovacs — All steady as Phase II trial readouts approach

Update

Healthcare

26.04.23

Ultimovacs — NIPU and INITIUM readouts incoming for UV1

Ultimovacs_resized

Update

Healthcare

21.02.23

Ultimovacs — Gathering steam with multiple inflections in FY23

Flash note

Healthcare

23.01.23

Ultimovacs — Phase II milestone as licensing potential nears

Flash note

Healthcare

21.12.22

Ultimovacs — Slight adjustment but trial continues as planned

Flash note

Healthcare

15.12.22

Ultimovacs — Prostate cancer trial patient enrolment complete

Update

Healthcare

11.11.22

Ultimovacs — On track for upcoming UV1 catalysts

Flash note

25.10.22

Ultimovacs — First patient in Phase II LUNGVAC study

edison tv

Healthcare

21.10.22

Ultimovacs – executive interview

Flash note

18.10.22

Ultimovacs — Biomarker insight into UV1 combination

edison tv

Healthcare

17.10.22

Ultimovacs – executive interview

Flash note

06.10.22

Ultimovacs — UV1 encouraging three-year survival data

Flash note

Healthcare

13.09.22

Ultimovacs — Further positivity for UV1

Update

Healthcare

19.08.22

Ultimovacs — UV1 development funded past key readouts

Flash note

Healthcare

19.08.22

Ultimovacs — Patient expansion in Phase I TENDU

Flash note

Healthcare

21.06.22

Ultimovacs — Positive Phase I survival data in melanoma

Update

Healthcare

15.06.22

Ultimovacs — Patient enrolment continues; catalysts approach

Flash note

Healthcare

13.05.22

Ultimovacs — UV1 Phase II data flow creeps closer

edison tv

Healthcare

07.03.22

Ultimovacs – executive interview

edison tv

Healthcare

16.01.22

Ultimovacs – executive interview Test

Update

Healthcare

13.12.21

Ultimovacs — New large indication for UV1

Update

Healthcare

03.09.21

Ultimovacs — Data continue to impress in Phase I UV1 study

Update

Healthcare

21.05.21

Ultimovacs — ORR impressive in Phase I UV1 plus Keytruda

Initiation

Healthcare

17.03.21

Ultimovacs — Cancer vaccine with virtually universal potential

edison tv

Healthcare

03.02.21

Ultimovacs – Edison Open House interview

QuickView

Healthcare

20.01.21

Ultimovacs — Phase II data from 500+ patients over 2022/23

QuickView

Healthcare

20.11.20

Ultimovacs — Cancer vaccine with near-universal potential